The presence of an immunosuppressive tumor microenvironment, a tumor-immune microenvironment, a low tumor mutation burden, higher expression of PD-1 and low expression of PD-L1, the presence of MDSCs, tumor heterogeneity, and racial differences make prostate tumors resistant to ICIs. The gene discussed is PDCD1; the disease is prostate neoplasm.